cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Catalyst Pharmaceuticals Inc
18 own
33 watching
Current Price
$20.87
$-0.33
(-1.56%)
1 Week Returns
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns
Created with Highstock 6.2.0

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,923.86M
52-Week High
52-Week High
24.64000
52-Week Low
52-Week Low
14.47000
Average Volume
Average Volume
0.83M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
9.1246
iconMarket Capitalization1,923.86M
icon52-Week High24.64000
icon52-Week Low14.47000
iconAverage Volume0.83M
iconDividend Yield--
iconP/E Ratio9.1246
What does the Catalyst Pharmaceuticals Inc do?
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.
Read More
How much money does Catalyst Pharmaceuticals Inc make?
Created with Highcharts 6.2.0Q1 2022Q4 2021Q3 2021Q2 2021Q1 20210 M10 M20 M30 M40 M50 M
Total Revenue
News & Events about Catalyst Pharmaceuticals Inc.
InvestorPlace
1 year ago
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Although people might not readily recognize these little-known stocks, they offer surprisingly robust upside potential. The post 7 Little-Known Stocks to Buy Now Before They Become the Next Big Thing appeared first on InvestorPlace...
Globe Newswire
1 year ago
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held today at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera will receive USD 90 million upfront at closing (USD75 million in cash and USD15 million equity investment), an additional USD10...
Globe Newswire
1 year ago
CORAL GABLES, Fla., May 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases today announced ...
Benzinga
2years ago
read more...
Globe Newswire
2years ago
CORAL GABLES, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases...
Frequently Asked Questions
Frequently Asked Questions
What is Catalyst Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Catalyst Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Catalyst Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Catalyst Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Catalyst Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Catalyst Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Catalyst Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Catalyst Pharmaceuticals Inc?
plus_minus_icon
What percentage is Catalyst Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Catalyst Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$20.87
$-0.33
(-1.56%)
1 Week Returns
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns
Created with Highstock 6.2.0

Get Started with as little as $1.00

Related Stocks
Mesoblast
Mesoblast
$13.28
$-0.17 (-1.26 %)
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$0.45
$-0.01 (-3.01 %)
Ascendis Pharma A/S
Ascendis Pharma A/S
$152.31
$2.00 (1.33 %)
22ND CENTURY GROUP INC
22ND CENTURY GROUP INC
$1.94
$-0.06 (-3.00 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Mesoblast
Mesoblast
$13.28
$-0.17 (-1.26 %)
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$0.45
$-0.01 (-3.01 %)
Ascendis Pharma A/S
Ascendis Pharma A/S
$152.31
$2.00 (1.33 %)
22ND CENTURY GROUP INC
22ND CENTURY GROUP INC
$1.94
$-0.06 (-3.00 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

*DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

All brands and logos used on this website are the property of their respective owners.

Get Started with as little as $1.00